SICOR Announces Tentative ANDA Approval for Fluconazole Injection IRVINE, Calif., Jan. 7 /PRNewswire-FirstCall/ -- SICOR Inc. today announced that the Food and Drug Administration (FDA) has issued a tentative approval of an Abbreviated New Drug Application (ANDA) submitted by its wholly owned subsidiary, SICOR Pharmaceuticals, Inc., for fluconazole injection. Fluconazole is an antifungal agent indicated for the treatment of vaginal candidiasis, oropharyngeal and esophageal candidiasis, and cryptococcal meningitis. SICOR's approval covers single-use vial sizes 200 mg/100 mL and 400 mg/200 mL. Based on data from IMS, a market research firm, U.S. sales of fluconazole injection in 2002 were approximately $175 million. The branded product, Diflucan(R), is marketed by Pfizer. SICOR Inc. is a vertically integrated, multinational pharmaceutical company that focuses on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients, or APIs, and generic biopharmaceuticals. Using internal research and development capabilities, together with operational flexibility and manufacturing and regulatory expertise, SICOR is able to take a wide variety of products from the laboratory to the worldwide market. Leveraging these capabilities, SICOR concentrates on products and technologies that present significant barriers to entry or offer first-to- market opportunities. SICOR operates several manufacturing facilities in the U.S., Western and Eastern Europe and Mexico, while maintaining its corporate headquarters in Irvine, California. For more information, please visit our website at http://www.sicor.com/ . Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company will receive final approval for fluconazole, whether the Company will successfully launch this product, whether fluconazole will receive market acceptance and those matters set forth in the risk factors section of Teva's Amendment to Registration Statement on Form F-4 filed with the Securities and Exchange Commission on December 12, 2003, regarding Teva's acquisition of SICOR Inc. These forward-looking statements represent SICOR's judgment as of the date of this press release. SICOR disclaims any intent or obligation to update these forward-looking statements. Additional Information About the Merger and Where to Find It This news release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any Teva shares, and is not a solicitation of a proxy. In connection with the proposed merger, Teva Pharmaceutical Industries Limited and SICOR Inc. filed a definitive proxy statement/prospectus with the Securities Exchange Commission on December 12, 2003, as part of an Amendment to Registration Statement on Form F-4. Investors and security holders are advised to read the definitive joint proxy statement/prospectus dated December 12, 2003, because important information is contained therein. The definitive proxy statement/prospectus has been sent to stockholders of SICOR Inc. in connection with the solicitation of their approval of the proposed merger of SICOR Inc. with a subsidiary of Teva Pharmaceutical Industries Limited. You may obtain a free copy of the Amendment to Registration Statement on Form F-4 and other documents filed by the companies with the Commission at the Commission's website at http://www.sec.gov/. The Amendment to Registration Statement also is available from Teva by contacting Teva Pharmaceutical Industries Limited, 5 Basel St. Petach Tikva 49131, Israel, Attention: Investor Relations (972-3-926-7554) and from SICOR Inc. by contacting SICOR Inc., 19 Hughes, Irvine, CA 92618, Attention: Investor Relations (949) 455-4879. Teva Pharmaceutical Industries Limited and SICOR Inc., and their respective directors and executive officers, may be deemed to be participants in the solicitation of proxies from the stockholders of SICOR Inc. in connection with the merger. Information about the directors and executive officers of SICOR Inc. and their interests in the merger, including their ownership of SICOR Inc., is set forth in the proxy statement for SICOR Inc.'s 2003 annual meeting of stockholders. Information about the directors and executive officers of Teva Pharmaceutical Industries Limited and their interests in the merger, including their ownership of Teva Pharmaceutical Industries Limited stock, is set forth in its annual report on Form 20-F for the year ended December 31, 2002. Investors may obtain additional information regarding the interests of such participants in the merger by reading the definitive proxy statement/prospectus. DATASOURCE: SICOR Inc. CONTACT: Laurie W. Little of SICOR Inc., +1-949-455-4879 Web site: http://www.sicor.com/

Copyright